01735nam 2200421Ia 450 991069639710332120071217144452.0(CKB)5470000002376856(OCoLC)184738729(EXLCZ)99547000000237685620071217d2007 ua 0engurmn|||||||||txtrdacontentcrdamediacrrdacarrierDrug safety[electronic resource] preliminary findings suggest weaknesses in FDA's program for inspecting foreign drug manufacturers : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives /statement of Marcia Crosse[Washington, D.C.] :U.S. Govt. Accountability Office,[2007]24 pages digital, PDF fileTestimony ;GAO-08-224 TTitle from title screen (viewed on Dec. 12, 2007)."For release ... November 1, 2007."Paper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.Includes bibliographical references.Drug safety DrugsSafety measuresDrugsInspectionDrugsSafety measures.DrugsInspection.Crosse Marcia1380679United States.Congress.House.Committee on Energy and Commerce.Subcommittee on Oversight and Investigations.United States.Government Accountability Office.GPOGPOBOOK9910696397103321Drug safety3449630UNINA